CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors

[1]  Linden J. Gearing,et al.  CD4^+ T cell calibration of antigen-presenting cells optimizes antiviral CD8^+ T cell immunity , 2023, Nature Immunology.

[2]  P. Benaroch,et al.  RELA tunes innate-like interferon I/III responses in human T cells , 2023, The Journal of experimental medicine.

[3]  H. van Eenennaam,et al.  CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment , 2023, Nature Communications.

[4]  Zachary R. Lewis,et al.  High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. , 2022, Nature biotechnology.

[5]  Xueda Hu,et al.  Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade , 2022, Nature Cancer.

[6]  K. Murphy,et al.  DCs at the center of help: Origins and evolution of the three-cell-type hypothesis , 2022, The Journal of experimental medicine.

[7]  R. Schreiber,et al.  Mechanisms of CD40-dependent cDC1 licensing beyond costimulation , 2022, Nature Immunology.

[8]  B. Zhu,et al.  Type I interferon-mediated tumor immunity and its role in immunotherapy , 2022, Cellular and Molecular Life Sciences.

[9]  I. Amit,et al.  The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response , 2022, Nature Cancer.

[10]  J. Gartner,et al.  Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers , 2022, Science.

[11]  Marieke E. Ijsselsteijn,et al.  Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival , 2022, Journal for ImmunoTherapy of Cancer.

[12]  Xueda Hu,et al.  Pan-cancer single-cell landscape of tumor-infiltrating T cells , 2021, Science.

[13]  A. Broeks,et al.  Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma , 2021, Nature Communications.

[14]  A. Bhutkar,et al.  Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. , 2021, Immunity.

[15]  T. Lawrence,et al.  The Role of Plasmacytoid Dendritic Cells in Cancers , 2021, Frontiers in Immunology.

[16]  Ash A. Alizadeh,et al.  Atlas of clinically distinct cell states and ecosystems across human solid tumors , 2021, Cell.

[17]  J. Borst,et al.  Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy , 2021, European journal of immunology.

[18]  J. Groom,et al.  Conversations that count: Cellular interactions that drive T cell fate , 2021, Immunological reviews.

[19]  Greg M. Delgoffe,et al.  Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion , 2021, Nature immunology.

[20]  J. Sibilia,et al.  Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING? , 2020, Frontiers in Immunology.

[21]  Gregory F. Wu,et al.  cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity , 2020, Nature.

[22]  Lingling Wu,et al.  cGAS-STING–mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy , 2020, Science Translational Medicine.

[23]  S. Tait,et al.  Mitochondrial DNA in inflammation and immunity , 2020, EMBO reports.

[24]  E. Graves,et al.  Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity , 2020, Nature Cancer.

[25]  A. Regev,et al.  Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma , 2019, Nature Medicine.

[26]  T. Severson,et al.  CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities , 2019, Nature Communications.

[27]  Marieke E. Ijsselsteijn,et al.  Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. , 2019, Molecular aspects of medicine.

[28]  S. Wyman,et al.  SLC19A1 transports immunoreactive cyclic dinucleotides , 2019, Nature.

[29]  M. Müller-Trutwin,et al.  Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection , 2019, Nature Metabolism.

[30]  Zemin Zhang,et al.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis , 2019, Nucleic Acids Res..

[31]  J. Alferink,et al.  Sources of Type I Interferons in Infectious Immunity: Plasmacytoid Dendritic Cells Not Always in the Driver's Seat , 2019, Front. Immunol..

[32]  K. Ishii,et al.  Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function , 2019, Life Science Alliance.

[33]  E. Borden.  Interferons α and β in cancer: therapeutic opportunities from new insights , 2019, Nature Reviews Drug Discovery.

[34]  Andrew J. Hill,et al.  The single cell transcriptional landscape of mammalian organogenesis , 2019, Nature.

[35]  S. Rutz,et al.  Ribonucleoprotein Transfection for CRISPR/Cas9‐Mediated Gene Knockout in Primary T Cells , 2018, Current protocols in immunology.

[36]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[37]  J. Borst,et al.  CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.

[38]  J. Mulé,et al.  Suppression of STING Signaling through Epigenetic Silencing and Missense Mutation Impedes DNA-Damage Mediated Cytokine Production , 2018, Oncogene.

[39]  J. Borst,et al.  CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness , 2017, Immunity.

[40]  Chiara Bonini,et al.  T memory stem cells in health and disease , 2017, Nature Medicine.

[41]  Lei Jin,et al.  Growing tumors induce a local STING dependent Type I IFN response in dendritic cells , 2016, International journal of cancer.

[42]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[43]  Fabian J Theis,et al.  Diffusion pseudotime robustly reconstructs lineage branching , 2016, Nature Methods.

[44]  S. Turner,et al.  T Cell Help Amplifies Innate Signals in CD8(+) DCs for Optimal CD8(+) T Cell Priming. , 2016, Cell reports.

[45]  M. Sadelain,et al.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.

[46]  Matthew E. Ritchie,et al.  Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production , 2014, Cell.

[47]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[48]  Ton N Schumacher,et al.  Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. , 2014, Human gene therapy methods.

[49]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[50]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[51]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[52]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[53]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[54]  A. Luster,et al.  CXCR3 ligands: redundant, collaborative and antagonistic functions , 2011, Immunology and cell biology.

[55]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[56]  Anna M. Keller,et al.  Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules , 2007, Proceedings of the National Academy of Sciences.

[57]  W. Cao,et al.  Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. , 2006, Blood.

[58]  J. Sprent,et al.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection , 2005, The Journal of experimental medicine.

[59]  H. Yagita,et al.  Induction of CD70 on Dendritic Cells through CD40 or TLR Stimulation Contributes to the Development of CD8+ T Cell Responses in the Absence of CD4+ T Cells1 , 2005, The Journal of Immunology.

[60]  T. Rowley,et al.  Cutting Edge: A Critical Role for CD70 in CD8 T Cell Priming by CD40-Licensed APCs1 , 2004, The Journal of Immunology.

[61]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[62]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[63]  Leo Lefrançois,et al.  Cytokine control of memory T-cell development and survival , 2003, Nature Reviews Immunology.

[64]  M. Bevan,et al.  Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.

[65]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[66]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.